Tag:
Athenagen
Latest Headlines
Latest Headlines
Ception Therapeutics pockets $63M in third round
Ception Therapeutics has rounded up $63 million in its third round of venture capital, with Essex Woodlands Health Ventures leading the way. Ception, which is based in Malvern Hill, PA, says that much of that money will be used to advance a late-stage biologic compound in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture …
ALSO NOTED: FDA staffers back Ketek; Abbott gains a majority of Kos shares; and much more...
> In advance of an FDA advisory committee meeting on the controversial antibiotic Ketek , agency staffers have concluded that the data on the Sanofi-Aventis therapy demonstrates that it is safe and effective. …
Press Release: Athenagen Initiates Phase II Clinical Trial in Alzheimer's Disease
Press Release: Athenagen Initiates Phase II Clinical Trial in Alzheimer's Disease
C&L: ImaRx CEO resigns
Dr. Evan Unger has resigned as president and CEO of ImaRx so that he will have more time to devote to the scientific development of the company. Brad Zakes and Greg Cobb will staff the Office of the CEO on an interim basis. Dr. Unger will remain a member of the ImaRx board of directors and will head the company's …
VC: NovaCardia lands $48M in second round
NovaCardia lands $48M in second round
Athenagen pockets $50M in second round
South San Francisco-based Athenagen has garnered $50 million in its second round and plans to use much of the money to push the development of its candidates for neurovascular diseases. Sanderling Ventures and Clarus Ventures led the round.
"Athenagen's internally generated AMD and beta-secretase inhibitor programs are potentially best-in-class molecules that have differentiated themselves from competitive programs," said Clarus' Dennis Henner. "Furthermore, the recently …
DEALS: Roche, Actelion ink $630M pact
Roche, Actelion ink $630M pact
ALSO NOTED: QuatRx pulls IPO; GSK's Avandamet gains new approval; and much more...
> QuatRx Pharmaceuticals has yanked its IPO, citing market conditions. Release
> The FDA has given GlaxoSmithKline's Avandamet approval as a front-line therapy for Type 2 diabetes. It won approval as a second-line therapy for some diabetes patients in 2002. Report
> Athenagen and Zapaq, both …
Athenagen acquires Osprey assets
Athenagen has acquired the assets of Osprey Pharmaceutical, including its lead drug candidate for Alzheimer's. Athenagen also nets a large library of analogs in the deal. Osprey's lead compound, GTS-21, is a selective alpha-7 nicotinic acetylcholine receptor agonist in Phase I. "GTS-21 is an excellent addition to our pipeline because it expands our nACh receptor-focused clinical portfolio with an additional therapeutic indication--Alzheimer's disease," said Athenagen CEO W. Scott …
C&L: Herrera named NeoPharm CEO
NeoPharm named Guillermo A. Herrera as president and CEO. Herrera spent 24 years at Abbott Laboratories and most recently served as senior vice president, international operations and president of Abbott International.
N. Anthony Coles , M.D., M.P.H., has been appointed as president and COO of NPS Pharmaceuticals. He had …
